AMGN - Amgen - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

AMGN is currently covered by 20 analysts with an average price target of $379.65. This is a potential upside of -$27.62 (-6.78%) from yesterday's end of day stock price of $407.27.

Amgen's activity chart (see below) currently has 947 price targets and 714 ratings on display. The stock rating distribution of AMGN is 34.85% BUY, 3.03% SELL and 62.12% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 90.69% with an average time for these price targets to be met of 557.7 days.

Highest price target for AMGN is $460, Lowest price target is $285, average price target is $379.65.

Most recent stock forecast was given by MORTEN HERHOLDT from HSBC on 10-Sep-2026.

What is Amgen?

Amgen is a biotechnology company that specializes in  developing, manufacturing, and delivering human therapeutics.

The company’s research focuses on six main therapeutic areas, which include inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience.

Products

Amgen produces drugs such as Enbrel, Neulasta, Prolia, Xgeva, Aranesp, KYPROLIS, and Repatha, which treat anemia, cardiovascular disease, multiple myeloma, osteoporosis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.

  • Enbrel
    • Treats inflammatory conditions such as plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. A healthcare provider or the patient injects Enbrel to inhibit tumor necrosis factor (TNF).
  • Neulasta
    • This product reduces the risk of infection in cancer patients undergoing chemotherapy, by stimulating the bone marrow to produce more white blood cells. It is administered by injection, usually 24 hours after chemotherapy.
  • Prolia
    • Treats postmenopausal women with osteoporosis by inhibiting RANKL, a protein involved in bone tissue breakdown. It is given by injection every six months. Prolia can increase bone density and reduce fractures.

History

Amgen was founded in 1980 and is headquartered in Thousand Oaks, California.

Currently out of the existing stock ratings of AMGN, 23 are a BUY (34.85%), 2 are a SELL (3.03%), 41 are a HOLD (62.12%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Sep-2023

$425

$10.39 (2.51%)

$320

22 days ago
(10-Sep-2026)

1/2 (50%)

$42.53 (11.12%)

797

Hold Since 07-Oct-2024

$400

$-14.61 (-3.52%)

$400

24 days ago
(08-Sep-2026)

32/35 (91.43%)

$6.83 (1.74%)

269

Buy Since 12-Apr-2024

$450

$35.39 (8.54%)

$450

24 days ago
(08-Sep-2026)

32/34 (94.12%)

$56.83 (14.45%)

567

Hold Since 10-Jan-2025

$435

$20.39 (4.92%)

$400

28 days ago
(04-Sep-2026)

20/21 (95.24%)

$-2.23 (-0.51%)

307

Buy Since 02-Jan-2025

$457

$42.39 (10.22%)

$427

1 months 12 days ago
(20-Aug-2026)

14/15 (93.33%)

$25.79 (5.98%)

160

Show more analysts

Please expand the browser size to see the chart

What is AMGN (Amgen) average time for price targets to be met?

On average it took 558 days for the stock forecasts to be reached, with an average price target met ratio of 90.69%.

Which analyst most recently updated their price target on AMGN (Amgen)?

Morten Herholdt

Which analyst has the most public recommendations on AMGN (Amgen)?

Morten Herholdt works at HSBC and has 3 price targets and 4 ratings on AMGN

Which analyst is the currently most bullish on AMGN (Amgen)?

David Amsellem with the highest potential upside of $68.67

Which analyst is the currently most reserved on AMGN (Amgen)?

Andrew Peters with the lowest potential downside of -$240.61
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?